CG009336

CG009336 is a targeted protein degrader developed by Cullgen for the treatment of inflammatory diseases. It is designed to induce the degradation of Interleukin-1 receptor-associated kinase 4 (IRAK4), a key protein involved in signaling pathways that drive inflammation, such as the Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) pathways. By degrading the IRAK4 protein rather than merely inhibiting its enzymatic activity, CG009336 potentially offers a more potent and durable suppression of pro-inflammatory cytokine production, providing a novel therapeutic approach for various inflammatory conditions.